Mericon Industries Inc. Recall: Dietary supplement contains excess amount of fluoride.
United States
TerminatedClass II
- Company
- Mericon Industries Inc.
- Product
- Monocal, Calcium & Fluoride Supplement, 100 Tablets; Mericon…
- Recall date
- September 23, 2016
- Terminated
- October 29, 2019
- Source
- FDA
Reason for recall
Dietary supplement contains excess amount of fluoride.
- - Recall initiated
- - Reported by source
- - Recall terminated
| Product description | UPC | Quantity | Lot / code information |
|---|---|---|---|
| Monocal, Calcium & Fluoride Supplement, 100 Tablets; Mericon Industries, Inc., Peoria, Illinois 61615; UPC: 0394-0105-02 | 0394-0105-02 | 158 bottles | Lot: 73007 |
Distribution
- NC
- MA
- NJ
- WI
- IA
- one customer in England
Official source record
- Agency
- FDA
- Dataset
- FDA Food Enforcement (Recalls)
- Recall number
- F-0419-2017
- Event ID
- 75360
- Status
- Terminated
- Classification
- Class II
- Company
- Mericon Industries Inc.
- Product description
- Monocal, Calcium & Fluoride Supplement, 100 Tablets; Mericon Industries, Inc., Peoria, Illinois 61615; UPC: 0394-0105-02
- Quantity
- 158 bottles
- Reason
- Dietary supplement contains excess amount of fluoride.
- Recall initiation date
- September 23, 2016
- Report date
- November 16, 2016
- Classification date
- Not published in this source record
- Termination date
- October 29, 2019
- Distribution pattern
- NC, MA, NJ, WI, IA, one customer in England
- UPC, lot, and code information
- UPC 0394-0105-02; Lot: 73007
- Voluntary or mandated
- Voluntary: Firm initiated
- Initial notification method
- Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
- Source last updated
- Not tracked separately from the Public Health Trace retrieval date below
- Public Health Trace retrieval date
Responsible company: Mericon Industries Inc.
A map highlighting the states named in the source's distribution description.
Shading reflects state-level totals only, as published by the source. It does not imply county-level or point-level precision.
| State | Distributed |
|---|---|
| North Carolina | 1 |
| Massachusetts | 1 |
| New Jersey | 1 |
| Wisconsin | 1 |
| Iowa | 1 |
States shown are extracted from the source's free-text distribution description above; a narrative description (e.g. "distributed nationwide") may not list individual states to extract.
Where this information comes from
View FDA enforcement record -- the specific openFDA record this summary was built from.
No separate FDA public notice was found for this enforcement record. The information below comes from FDA's Recall Enterprise System through openFDA.
FDA Enforcement Reports -- FDA's general, official recall and enforcement information.
Technical source data
View raw source data -- the machine-readable record this page's information was built from.
Retrieved by Public Health Trace:
Frequently asked questions
What does a Class II mean?
A situation in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote.
Is this recall still active?
According to FDA, this recall's status is "Terminated." Always confirm the current status using the source links below, since status can change after Public Health Trace last retrieved this record.
What should I do if I have this product?
Follow the instructions published by the responsible agency (see the source links below) -- recall guidance (e.g. dispose of the product, return it for a refund, or check for a specific lot number) varies by recall and is set by that agency, not by Public Health Trace.
Where can I find more official information?
The source links below, published by FDA, are the authoritative record for this recall, including any updates issued after this summary was retrieved.
This summary is based on the official source record referenced above. Public Health Trace does not state that any company or product is unsafe beyond what the official source has published. Read the full medical disclaimer.
